SCHEMBL4268355

SCHEMBL4268355

Cc1cc2nc(N)nnc2cc1-c1ccc(CO)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 6/20 0.47
▸ PIK3CG P48736 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ DHFR P00374 5/20 0.34
▸ CYP2A6 P11509 2/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2E1 P05181 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C8 P10632 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2B6 P20813 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4275286 0.80 SRC (0.43) SRCPIK3CGDHFRPABPC1BACE1
SCHEMBL27928483 0.80 SRC (0.40) SRCPIK3CGALDH1A1DHFRPABPC1
SCHEMBL4276194 0.72 DHFR (0.49) SRCDHFR
SCHEMBL4268061 0.67 SRC (0.43) SRCPIK3CGDHFRPABPC1
SCHEMBL4271141 0.67 SRC (0.63) SRCPIK3CGDHFR
SCHEMBL13609525 0.66 SRC (0.46) SRCPIK3CGDHFRPABPC1
SCHEMBL28168138 0.65 HPGD (0.53) MEN1ALDH1A1GLAMAPTHPGD
SCHEMBL4265960 0.64 DHFR (0.51) SRCPIK3CGALDH1A1MAPTDHFR
SCHEMBL4275233 0.64 SRC (0.43) SRCPIK3CGDHFRPABPC1
SCHEMBL4266181 0.63 PABPC1 (0.52) SRCPIK3CGALDH1A1PABPC1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 — — EP disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 — — US disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 — — EP disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 — — US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 — — US disclosed
CN-101426772-A Benzotriazine inhibitors of kinases TARGEGEN INC (US) 2009-05-06 — — CN disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 — — US disclosed
EP-1809614-A2 BENZOTRIAZINE INHIBITORS OF KINASES Targegen, Inc. (US) 2007-07-25 — — EP disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 — — US disclosed
WO-2005096784-A2 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES SRC, CAMK4, CAMK2G SRC 1/4885PIK3CG 756/4885MEN1 4284/4885
US-20090275569-A1 Benzotriazine Inhibitors of Kinases SRC, CAMK4, CAMK2G SRC 1/4885PIK3CG 756/4885MEN1 4284/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G SRC 1/4885PIK3CG 756/4885MEN1 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback